Semarion has raised $3.8 million to scale its next-generation cell assay technology and expand manufacturing of its microcarrier platform.  The company, a University of Cambridge spin-out from the Cambridge Laboratory, will use investment to facilitate commercial expansion and scale manufacturing of its SemaCyte platform, which enables adherent cell models to be handled as assay-ready, barcoded reagents for more flexible, […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!